This is a preview of subscription content, log in via an institution to check access.
Notes
This profile has been selected from R&D Insight−, a pharmaceutical intelligence database produced by Adis International Ltd.
References
Wang B, Osborn K, Blaisdell P, Brenner R, Turner S, et al. Pharmacokinetics of calcimimetic AMG 073 in secondary hyperparathyroidism. Clinical Pharmacology and Therapeutics 69: P91, Feb 2001
Peacock M, Bilezekian JP, Turner SA, Guo MD, McCary LC, et al. Long-term treatment with the calcimimetic AMG 073 in patients with primary hyperparathyroidism. 84th Annual Meeting of the Endocrine Society: 92–93, 19 Jun 2002. Indiana University School of Medicine, Indianapolis, Indiana, USA; Amgen Inc., Thousand Oaks, California, USA
Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology. 13: 1017–1024, Apr 2002. Goodman WG, Univ Calif Los Angeles, Med Ctr, Div Nephrol, Sch Med, Dept Med, 7–155 Factor Bldg, 10833 Le Conte Ave, Los Angeles, CA 90095 USA
Amgen. First-In-Class Oral Calcimimetic Shown To Reduce Parathyroid Hormone Levels In Chronic Kidney Disease. Media Release: 3 Nov 2002. Available from URL: http://www.amgen.com
NPS Pharmaceuticals Inc. Positive phase II data on calcimimetics reported at medical meetings (NPS Pharmaceuticals). Media Release: [2 pages], 18 Oct 2001. Available from URL: http://www.npsp.com
Rights and permissions
About this article
Cite this article
Cinacalcet. Drugs in R&D 4, 39–41 (2003). https://doi.org/10.2165/00126839-200304010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200304010-00006